Literature DB >> 8033398

Sweet's syndrome--therapy with cyclosporin.

P von den Driesch1, C Steffan, A Zöbe, O P Hornstein.   

Abstract

We report the case of a 39-year-old female patient suffering from Sweet's syndrome after an upper respiratory tract infection. Cyclosporin A at a dose of 10 mg/kg per day was given as initial treatment. Skin lesions and general malaise resolved within 9 days. The cyclosporin dose was decreased within 21 days, without recurrence of the eruption. Cyclosporin is a potent inhibitor of T lymphocytes, but affects granulocyte and monocyte functions as well. Success of treatment in our case shows that cyclosporin represents an alternative to steroid treatment in patients with Sweet's syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033398     DOI: 10.1111/j.1365-2230.1994.tb01187.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  5 in total

1.  Sweet syndrome secondary to inflammatory bowel disease.

Authors:  Malcolm M Wells; William Stecho; Bret Wehrli; Nitin Khanna
Journal:  Can J Gastroenterol       Date:  2013-03       Impact factor: 3.522

Review 2.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

Review 3.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

4.  Sequential occurrence of recurrent Sweet syndrome and erythema nodosum without an underlying secondary cause: a case report.

Authors:  Chamila Mettananda; Hansika Peiris; Ahamed Uwyse
Journal:  J Med Case Rep       Date:  2022-02-25

Review 5.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.